Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCDANASDAQ:CNSPNASDAQ:IMNNNASDAQ:RLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$1.95-9.3%$2.28$1.63▼$4.66$11.13M0.83261,760 shs75,679 shsCNSPCNS Pharmaceuticals$0.83-6.1%$1.03$0.73▼$148.00$4.80M2.65696,487 shs98,987 shsIMNNImunon$0.80+8.1%$1.09$0.37▼$3.65$12.98M2.133.67 million shs1.77 million shsRLMDRelmada Therapeutics$0.60-1.6%$0.58$0.24▼$4.47$20.25M0.64967,098 shs194,611 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia-9.30%-3.47%-9.72%-8.88%-34.34%CNSPCNS Pharmaceuticals-6.14%+8.70%-21.05%-36.05%-98.96%IMNNImunon+8.11%-13.21%-70.03%-24.17%-31.03%RLMDRelmada Therapeutics-1.59%-1.59%-16.67%+119.41%-79.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCDABioCardia3.7714 of 5 stars3.85.00.00.03.02.50.6CNSPCNS Pharmaceuticals1.5328 of 5 stars3.32.00.00.01.60.00.6IMNNImunon2.8498 of 5 stars3.44.00.00.03.80.00.6RLMDRelmada Therapeutics4.758 of 5 stars3.15.00.04.41.94.21.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia 3.50Strong Buy$25.001,182.05% UpsideCNSPCNS Pharmaceuticals 2.50Moderate Buy$25.002,930.30% UpsideIMNNImunon 2.75Moderate Buy$15.501,837.50% UpsideRLMDRelmada Therapeutics 2.25Hold$5.00732.92% UpsideCurrent Analyst Ratings BreakdownLatest CNSP, BCDA, RLMD, and IMNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025CNSPCNS PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/19/2025IMNNImunonD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/19/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/13/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$29.00 ➝ $17.005/7/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardia$60K168.35N/AN/A$0.18 per share10.83CNSPCNS PharmaceuticalsN/AN/AN/AN/A$5.37 per shareN/AIMNNImunon$500K28.06N/AN/A$0.29 per share2.76RLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$7.95M-$2.33N/AN/AN/AN/A-30,792.60%-223.06%8/12/2025 (Estimated)CNSPCNS Pharmaceuticals-$14.86M-$3,748.50N/A∞N/AN/A-385.41%-193.20%8/13/2025 (Estimated)IMNNImunon-$18.62M-$1.36N/AN/AN/AN/A-427.98%-175.03%8/13/2025 (Estimated)RLMDRelmada Therapeutics-$79.98M-$2.51N/AN/AN/AN/A-181.26%-151.23%8/6/2025 (Estimated)Latest CNSP, BCDA, RLMD, and IMNN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNSPCNS PharmaceuticalsN/A-$1.58N/A-$1.58N/AN/A5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A5/12/2025Q1 2025IMNNImunon-$0.35-$0.28+$0.07-$0.28N/AN/A5/12/2025Q1 2025RLMDRelmada Therapeutics-$0.31-$0.58-$0.27-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A0.360.36CNSPCNS PharmaceuticalsN/A4.944.94IMNNImunonN/A0.880.88RLMDRelmada TherapeuticsN/A5.295.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%CNSPCNS Pharmaceuticals14.02%IMNNImunon4.47%RLMDRelmada Therapeutics45.24%Insider OwnershipCompanyInsider OwnershipBCDABioCardia20.00%CNSPCNS Pharmaceuticals0.07%IMNNImunon5.96%RLMDRelmada Therapeutics20.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia405.18 million4.14 millionOptionableCNSPCNS Pharmaceuticals55.46 million5.46 millionNot OptionableIMNNImunon3017.54 million16.50 millionNot OptionableRLMDRelmada Therapeutics1033.19 million26.32 millionOptionableCNSP, BCDA, RLMD, and IMNN HeadlinesRecent News About These CompaniesRelmada Therapeutics' Market Cap Drops To US$22m Leaving Insiders With LossesJune 28 at 12:21 PM | uk.finance.yahoo.comRelmada Therapeutics, Inc. (RLMD) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRLMD - Relmada Therapeutics Inc Executives - MorningstarJune 24, 2025 | morningstar.comMRelmada Therapeutics Appoints Dr. Raj S. Pruthi as Chief Medical Officer for Urology to Advance NDV-01 Program for Bladder CancerJune 17, 2025 | quiverquant.comQRelmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-UrologyJune 17, 2025 | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Purchases $22,000.00 in StockMay 21, 2025 | insidertrades.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comRelmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comRelmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comRelmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025May 8, 2025 | globenewswire.comRelmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder CancerApril 28, 2025 | nasdaq.comRelmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025April 28, 2025 | globenewswire.comRelmada Therapeutics to hold a virtual meetingApril 27, 2025 | markets.businessinsider.comUPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025April 27, 2025 | globenewswire.comRelmada Therapeutics to Host KOL Event on Phase 2 NDV-01 DataApril 24, 2025 | globenewswire.comUPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025April 14, 2025 | globenewswire.comRelmada Therapeutics To Present NDV-01 Data at AUA2025April 14, 2025 | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comQ4 2024 Relmada Therapeutics Inc Earnings CallMarch 29, 2025 | uk.finance.yahoo.comRelmada reconsiders phase 2 plans to test magic mushroom extract for obesityMarch 28, 2025 | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNSP, BCDA, RLMD, and IMNN Company DescriptionsBioCardia NASDAQ:BCDA$1.95 -0.20 (-9.30%) As of 06/30/2025 04:00 PM EasternBioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.CNS Pharmaceuticals NASDAQ:CNSP$0.82 -0.05 (-6.14%) As of 06/30/2025 04:00 PM EasternCNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Imunon NASDAQ:IMNN$0.80 +0.06 (+8.11%) As of 06/30/2025 04:00 PM EasternImunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Relmada Therapeutics NASDAQ:RLMD$0.60 -0.01 (-1.59%) As of 06/30/2025 04:00 PM EasternRelmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
